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Although prostate cancer (PrCa) is one of the most common cancers in men in Western countries, little is known about the inherited
factors that influence PrCa risk. On the basis of the fact that BRIP1/FANCJ interacts with BRCA1 and functions as a regulator of DNA
double-strand break repair pathways, and that germline mutations within the BRIP1/FANCJ gene predispose to breast cancer, we
chose this gene as a candidate for mutation screening in familial and young-onset PrCa cases. We identified a truncating mutation,
R798X, in the BRIP1/FANCJ gene in 4 out of 2714 UK PrCa cases enriched for familial (2 out of 641; 0.3%) and young-onset cases
(2 out of 2073; 0.1%). On screening 2045 controls from the UK population, we found one R798X sequence alteration (0.05%; odds
ratio 2.4 (95% CI 0.25–23.4)). In addition, using our data from a genome-wide association study, we analysed 25 SNPs in the
genomic region of the BRIP1/FANCJ gene. Two SNPs showed evidence of association with familial and young-onset PrCa (rs6504074;
Ptrend¼0.04 and rs8076727; Ptrend¼0.01). These results suggest that truncating mutations in BRIP1/FANCJ might confer an increased
risk of PrCa and common SNPs might also contribute to the alteration of risk, but larger case–control series will be required to
confirm or refute this association.
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Prostate cancer (PrCa) aggregates in families, in a consistent manner
with an important inherited component (reviewed in Edwards and
Eeles, 2004). The genetic components underlying this familial risk
have, however, proved difficult to identify. Genetic studies using
linkage analysis in high-risk families have identified several possible
susceptibility loci (Tavtigian et al,2 0 0 1 ;C a r p t e net al, 2002), but none
of them have been definitively established (Easton et al, 2003). It
seems likely now that susceptibility to PrCa is mediated, at least
partially, through a combination of multiple low-penetrance loci
(Haiman et al, 2007; Eeles et al,2 0 0 8 ;T h o m a set al, 2008).
Genome-wide association studies (GWAS) have identified
common variants in several regions that are associated with PrCa
risk (Eeles et al, 2008; Gudmundsson et al, 2008; Thomas et al,
2008). In addition, resequencing of candidate genes, notably those
involved in DNA double-strand break repair, has identified rarer
variants associated with a more substantial risk. The most
important of these is BRCA2 mutations, which confer a risk of
approximately five-fold, but there is evidence that truncating
mutations in NBS1 and CHEK2 also confer susceptibility to PrCa
(Dong et al, 2003; Edwards et al, 2003; Cybulski et al, 2004; Agalliu
et al, 2007).
The BRIP1/FANCJ gene encodes a helicase in which the
C-terminal domain is reported to interact with BRCA1 (Cantor
et al, 2001). The BRIP1 gene spans 180kb, comprises 20 exons
and encodes a protein of 1249 amino acids. It is located
on chromosome 17q22, distal to BRCA1, which is at 17q21.
BRIP1/FANCJ has an important role in BRCA-associated DNA
damage repair functions, works as a DNA-dependent ATPase and a
DNA helicase, and is essential for DNA repair and genomic
stability. It forms a complex with the BRCT domain of BRCA1, and
this is important for the role of BRCA1 in its DNA double-strand
break repair function (Levitus et al, 2006).
Germline mutations in BRIP1/FANCJ are associated with
Fanconi anaemia, a chromosomal instability syndrome charac-
terised by developmental abnormalities and predisposition to
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scancer (Levitus et al, 2005). Truncating mutations in the BRIP1/
FANCJ gene have recently been shown to be associated with a
moderate risk of breast cancer (Seal et al, 2006). Given the
observed associations of PrCa with other DNA repair genes, we
considered BRIP1/FANCJ as an attractive candidate for PrCa-
predisposition gene.
MATERIALS AND METHODS
Whole blood samples from PrCa cases were collected as part of the
UK Genetic Prostate Cancer Study (UKGPCS), a national study of
familial and young cases of PrCa. Familial samples were from 192
cases with two affected relatives (‘strong family history’) and 449
other samples with one affected relative (‘some family history’).
One person per family was used for sequence analysis. Wherever
possible, the youngest affected family member was considered.
Young-onset cases comprised 2073 men with a diagnosis of PrCa at
age p60 years. All self-reported non-Caucasians were excluded.
The study was approved by the multiregional ethics committee and
all patients gave informed consent. All PrCa diagnosis was based
on the verification of the histological report or death certificate.
Caucasian controls comprised 2045 blood DNA samples, which
were selected through the ProtecT study. ProtecT is a national
study of community-based PSA testing and a randomised trial of
subsequent PrCa treatment. Men between the ages of 50 and 69
years are recruited through general practices in nine centres in the
UK. Ethnically matched controls were sampled from these centres
to match approximately the geographical distribution of the cases.
DNA was extracted using standard methods as described in Eeles
et al (2008).
The full coding sequence and exon–intron boundaries of the
192 familial samples were analysed by sequencing. The sequencing
was carried out using the BigDyeTerminator v3.2 Cycle Sequencing
kit and the 3700 automated sequencer (Applied Biosystems, Foster
City, CA, USA).
All the additional samples, 2073 young-onset cases and 2045 UK
population controls were tested for the R798X sequence variant by the
50nuclease assay (Taqmant) using the ABIPrism 7900HT sequence
detection system according to the manufacturer’s instructions. Primers
and probes were supplied directly by Applied Biosystems (http://
www.appliedbiosystems.com/) as Assays-By-Designt.
We had earlier carried out a GWAS, involving 1854 of the PrCa
cases and 1894 controls using the Illumina Infinium Human-
Hap550 array (Eeles et al, 2008). From these data, we identified 25
SNPs from the 270-kb region covering the genomic sequences of
BRIP1/FANCJ, which were used to obtain evidence for associations
between common variants and PrCa risk.
Significance tests, odds ratios (ORs) and confidence limits were
computed using standard methods. For the SNPs, both Cochran–
Armitage trend tests and 2-degrees-of-freedom tests were calcu-
lated. For Hardy–Weinberg equilibrium and Armitage trend
testing, we used the public software developed by Tim M Strom
and Thomas F Wienker (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl).
RESULTS
Initially, a set of genomic DNA samples representing the youngest
affected individual from 192 multiple case PrCa families was
screened. The full coding sequence and exon–intron boundaries of
the BRIP1/FANCJ were analysed by sequencing. A truncating
mutation, R798X (1 out of 192, 0.52%) was identified in the
proband from a family with three affected brothers (Table 1). The
pedigree and the result of the segregation analysis are shown in
Figure 1. The available blood samples were tested for this germline
Table 1 Recurring mutation in BRIP1/FANCJ in prostate cancer
Mutation Study group
No. of samples
screened
No. of
mutations Frequency P-value
p.Arg798Stop
R798X
Cases with strong family history (proband from families
of three or more PrCa)
192 1 0.52 % 0.16
Cases with some family history (proband from
families of two PrCa)
449 1 0.22% 0.33
Young-onset cases (diagnosed at p60 years of age) 2073 2 0.10% 0.51
All young-onset or familial PrCa tested 2714 4 0.14% 0.29
UK population controls 2045 1 0.05%
PrCa¼prostate cancer.
PC 63
R789X
PC 63
WT
PC 56
R789X
SC 
49
WT 
WT LEU 2 WT WT
Figure 1 Prostate cancer (PC) family with the R798X nonsense mutation in BRIP1/FANCJ. Wild-type (WT) labels on individuals tested but non-carriers of
R798X, Leu¼leukaemia, SC¼stomach cancer. (The pedigree has been modified to maintain confidentiality.)
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smutation and one affected brother carried the mutation, whereas
the unaffected brother did not. Only a paraffin-embedded tissue
sample (biopsy) was available from the third affected brother, and
sequencing the DNA sample from this did not show the mutation.
Blood samples from his three sons were also tested and were all
found to be non-carriers for the R798X mutation. In addition to
this deleterious mutation, several missense mutations were
identified in the 192 familial samples, as presented in Table 2.
No other mutations that were predicted to truncate the protein
were identified.
To establish the contribution of the BRIP1/FANCJ R798X
mutation to PrCa predisposition, we screened a further 449
samples with a single affected relative and 2073 young-onset PrCa
cases, (individuals diagnosed with PrCa before 60 years of age with
no family history) and 2045 controls. The R798X mutation was
present in two of the young-onset cases (0.10%), in one of the
familial cases (0.22%), and in one of the controls (0.05%) (Table 1).
The ages of onset of the mutation carriers were 49 and 60 years.
Neither case had a family history of PrCa. However, one of these
mutation carriers had a family history of other cancers and
malformations, which appear characteristic of Gorlin syndrome.
The familial case had one affected second-degree relative with an
unknown age of onset, and also had relatives affected with other
cancers (colon and stomach cancer).
On the basis of our data, the estimated OR for PrCa was 2.4 (95%
CI 0.25–23.4). If the control data of Seal et al (2006) are also
considered in our analysis, the estimate is somewhat more precise
(OR 2.5, 95% CI 0.41–14.7) but still not significantly different
from 1.
We found five other amino-acid substitutions in the 192 familial
samples sequenced (Table 2). All have been reported earlier (Seal
et al, 2006; Gue ´nard et al, 2008). All of these sequence variants
were also found in the control series. The common variant
p.Pro919Ser showed some evidence of an association with risk
(Ptrend¼0.034) in this set of cases with strong family history.
However, this SNP (rs4986764) was also included on the Illumina
550k array used in our GWAS (Eeles et al, 2008). In this larger
study of familial and young-onset cases there was no evidence of
association with PrCa (Ptrend¼0.48). None of the four rare variants
showed a difference in frequency between cases and controls.
We also analysed the genotype frequencies of 25 SNPs from the
Illumina 550k array in the genomic region of FANCJ/BRIP1 for
1853 PrCa cases and 1880 control individuals (Eeles et al, 2008).
We found significant differences in genotype frequencies between
cases and controls for two SNPs: rs6504074 and rs8076727
(Table 3). The estimated per allele OR for rs6504074 was 1.10
(Ptrend¼0.029); this rose to 1.20 (Ptrend¼0.01) when the analysis
was restricted to familial cases. The estimated OR for rs8076727
was 1.29 (P¼0.01); this rose to 1.39 (P¼0.01) for familial cases.
DISCUSSION
We have identified a recurrent deleterious mutation in the BRIP1/
FANCJ gene in a set of familial and young-onset PrCa cases.
This truncating mutation has been reported earlier in four
Fanconi anaemia subtype J families of diverse geographic origin
(Levitus et al, 2005) and in five breast cancer families (Seal et al,
2006), suggesting that it is a relatively ancient founder mutation.
The frequency of this mutation in our control population is almost
identical to that found in the study by Seal et al (2006) (1 in 2081).
This recurrent R798X mutation in exon 17 predicts a truncated
protein in which the helicase motif VI and the BRCA1 interacting
regions are deleted. BRIP1/FANCJ binds directly to the C-terminal
BRCA repeats of BRCA1 and this interaction is regulated in a cell-
cycle-dependent manner. However, in the Fanconi anaemia
pathway for DNA crosslink repair, BRIP1/FANCJ functions
independently of this interaction (Bridge et al, 2005).
BRIP1/FANCJ encodes a DEAH-box helicase and can directly
interact with DNA (Bridge et al, 2005). It can unwind DNA
structures such as Holliday junctions formed during homologous
recombination, suggesting an association with some DNA repair
Table 2 Non-synonymous sequence variants found in BRIP1/FANCJ in familial PrCa
Cases, n (%) Controls
a, n (%)
Exon Nucleotide change dbSNP ID Protein change n¼192 n¼2081
6 c.517C4T rs4988345 p.Arg173Cys 1 (0.52%) 24 (1.10%)
c.577G4A rs4988346 p.Val193Ile 1 (0.52%) 14 (0.67%)
c.584T4C p.Leu195Pro 2 (1.04%) 6 (0.28%)
7 c.890A4G p.Lys297Arg 2 (1.04%) 6 (0.28%)
19 c.2755C4T rs4986764 p.Pro919Ser Pro/Ser 83 (43.00%) 970 (46.0%)
Ser/Ser 44 (22.9%) 328 (15.7%)
PrCa¼prostate cancer.
aData from Seal et al (2006).
Table 3 Prostate cancer genotype specific risk for two SNPs in BRIP1/FANCJ genomic region
GG TG TT Per allele OR (95% CI) OR Hom (95% CI) OR Het (95% CI) PHet Ptrend
rs6504074
Familial 345 274 64 1.20 (1.04–1.37) 1.57 (1.13–2.17) 1.13 (0.94–1.35) 0.21 0.01
Young 618 453 87 1.07 (0.94–1.20) 1.19 (0.89–1.59) 1.04 (0.89–1.21) 0.62 0.28
All 963 727 151 1.11 (1.00–1.23) 1.33 (1.03–1.71) 1.07 (0.94–1.23) 0.32 0.04
Control 1031 727 122
rs8076727
Familial 373 261 46 1.20 (1.04–1.38) 1.39 (0.96–2.00) 1.21 (1.01–1.46) 0.04 0.01
Young 658 432 72 1.12 (1.00–1.27) 1.23 (0.90–1.69) 1.14 (0.98–1.33) 0.10 0.06
All 1031 693 118 1.13 (1.03–1.28) 1.29 (0.97–1.70) 1.17 (1.017–1.336) 0.03 0.01
Control 1124 648 100
OR¼odds ratio; SNP¼single nucleotide polymorphism.
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sprocesses (Levitus et al, 2006). It is interesting that most of the
Fanconi anaemia genes encode proteins that form a nuclear core
complex with a function of monoubiquitination of FANCD2, but
FANCD1 (BRCA2) and BRIP1/FANCJ function downstream of this
and they both have a more defined role in DNA damage repair.
We have reported earlier that 2% of men diagnosed with PrCa at
o55 years had a germline mutation in the BRCA2 gene (Edwards
et al, 2003). BRCA2 is a high-risk breast cancer predisposition gene
and is also known as FANCD1, responsible for causing FA-D1. It is
therefore plausible that truncating mutations in BRID1/FANCJ also
predispose to PrCa. Our results for the R798X mutation are
consistent with a moderate risk of PrCa, comparable to that for
breast cancer, but larger numbers will be required to confirm this.
We found five other amino-acid substitutions in the 192 familial
samples sequenced (Table 2), all of which have been reported
earlier (Seal et al, 2006; Gue ´nard et al, 2008). Three of these
variants are situated within the Rad3-related DNA helicase domain
(res.1–888) and one, the common p.Pro919Ser variant, is within
the BRCA1-binding domain (Bridge et al, 2005). The p.Arg173 is a
strongly conserved residue in mammals, whereas the other
variants are poorly conserved in other species (Gue ´nard et al,
2008). We found no evidence for significant association between
these sequence variants and PrCa risk.
We have also evaluated the association between 25 common
SNPs and the risk of PrCa in a case–control design and found two
SNPs significantly associated with PrCa risk. Both of the associated
SNPs are in intron 6. These associations, although nominally
significant, do not reach the stringent levels of significance
appropriate for candidate gene or genome-wide scans, and could
have occurred by chance. However, if verified in larger series,
they could be markers for common variants in BRID1/FANCJ
influencing the risk.
In conclusion, we report that deleterious mutations in BRIP1/
FANCJ occur in a modest number of familial and young-onset
PrCa cases. In addition, we found evidence of association with two
common SNPs. These observations warrant further evaluation in
independent case–control studies.
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